CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

TociliuzumabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia

This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe COVID-19 pneumonia.

NCT04363736 COVID-1 COVID-19 Pneumonia Drug: Tociliuzumab
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: Concentration of C-Reactive Protein (CRP)

Time: Day 7

Secondary Outcomes

Measure: Serum Concentration of Interleukin-6 (IL-6)

Time: Days 1, 3, 7, 14, and 28

Measure: Serum Concentration of Soluble Interleukin Receptor (sIL-6R)

Time: Days 1, 3, 7, 14, and 28

Measure: Serum Concentration of Ferritin

Time: Days 1, 3, 7, 14, and 28

Measure: Serum Concentration of TCZ Following Administration of 8 mg/kg IV TCZ

Time: At pre-defined intervals from first TCZ administration to Day 28

Measure: Serum Concentration of TCZ Following Administration of 4 mg/kg IV TCZ

Time: At pre-defined intervals from first TCZ administration to Day 28

Measure: Clinical Status, as Assessed Using a 7-Category Ordinal Scale

Time: Days 14 and 28

Measure: Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of Time: Up to Day 28

Measure: Time to Improvement in at Least Two Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status

Time: Up to Day 28

Measure: Duration of Supplemental Oxygen Use

Time: Up to Day 28

Measure: Incidence of Intensive Care Unit (ICU) Stays

Time: Up to Day 28

Measure: Incidence of Mechanical Ventilation

Time: Up to Day 28

Measure: Duration of ICU Stay

Time: Up to Day 28

Measure: Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)

Time: Up to Day 28

Measure: Mortality Rate

Time: Days 7, 14, 21, 28, and 60

Measure: Time to Hospital Discharge or "Ready for Discharge"

Time: Up to Day 28

Measure: Frequency of Addition of a Second Dose of TCZ

Time: Up to Day 28

Measure: Pecentage of Participants with Adverse Events

Time: Up to Day 28

Measure: SARS-CoV-2 (COVID-19) Viral Load Over Time

Time: Up to Day 28

Measure: Time to Real-Time Polymerase Chain Reaction (PCR) Virus Negativity

Time: Up to Day 28

Measure: Proportion of Participants with any Post-Treatment Infection

Time: Up to Day 28

Related HPO nodes (Using clinical trials)

HP:0002090: Pneumonia
Genes 208
TIMM8A DNAH9 GAS8 DNAH11 TNFRSF11A TBC1D24 SPAG1 MS4A1 GAS2L2 CCDC151 NIPBL BTK LIG4 NFKB2 TCIRG1 IGLL1 RNF168 STAT3 TAF1 RSPH4A CFTR NME8 DNAAF4 LEP CCDC65 NADK2 CD55 COL11A2 NHLRC1 PEPD CFAP300 LTBP3 WAS DNAI1 TBCD IL2RG GFI1 NBN RSPH1 CCDC39 PMM2 ICOS TNFSF12 IFNGR1 CARD11 SFTPC DNAL1 OFD1 ZMYND10 IL21R FMO3 SLC35A1 PLOD1 ORC6 RAG2 CACNA1C GAS8 RYR1 CFAP298 GNPTAB TNFRSF13B KDM6A PANK2 RANBP2 CYBA USB1 UBB DOCK8 ADA DNAAF2 KMT2D SAMD9 MUC5B IL7R DNAAF1 ICOS RAG2 CARD11 PTPRC ALMS1 NOTCH3 NSMCE3 DNAI1 TNFRSF13C GRHL3 EGFR IL2RG DNAAF6 PNP DNAH5 SETBP1 CR2 CD3E ADA MASP2 SFTPA2 ACTA1 RAC1 TTC25 FCGR2A ZAP70 SPEF2 IGHM DNAAF5 NBN CD247 DDR2 CD19 ACADVL KIAA0586 TK2 BLNK ARMC4 SGCG RAG1 CXCR4 NCF1 SRP54 FOXP3 IRF8 CFAP221 RNU4ATAC KCNJ6 LRBA CD3D P4HTM SELENON CCDC114 TNFRSF13B PLG DCLRE1C SLC25A24 DCLRE1C ICOS IL7R FOXJ1 JAK3 IL2RG CASP8 RAG1 OSTM1 CFAP410 CCNO NCF2 UNC119 TNFRSF13C JAK3 RNF125 STK36 POLA1 CD19 CR2 DNAH1 RSPH3 RSPH9 CYBB DRC1 DCLRE1C CCDC103 DNAAF3 LRRC56 PIGN LRRC6 SP110 PRKCD ACP5 CCDC40 SLC35C1 BTK MTHFD1 PGM3 RAG1 TERT CHD7 CFB TGFB1 RNU4ATAC SMARCD2 NKX2-1 OFD1 ZBTB24 BTK DNAI2 WDR19 ZAP70 CD79B CD81 COL11A2 NFIX RAG2 ELANE AFF4 NFKB1 IL2RG TNFRSF13C TNFSF12 CCDC114 ADA GBA DNAJB13 RPGR CSPP1 RMRP EPM2A DNMT3B NFKB2 MCIDAS HYDIN
Protein Mutations 6
A2063G G551D K55R L460D R287Q S1009A
SNP 0